Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT1390B in Relapsed/Refractory Acute Myeloid Leukemia
NCT07441980Phase 1Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Mar 2026
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CT1390B in acute myeloid leukemia (AML), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Adverse Events at 12 months, Dose-limiting toxicity at 28 days and 1 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
CT1390B
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07441980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07441980.